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ABSTRACT
Exercising women report three to six times more ACL 
tears than men, which happen, in the majority of cases, 
with a non- contact mechanism. This sex disparity has, 
in part, been attributed to the differences in reproductive 
hormone profiles between men and women. Many studies 
have shown that anterior knee (AK) laxity and the rate 
of non- contact ACL injuries vary across the menstrual 
cycle, but these data are inconsistent. Similarly, several 
studies have investigated the potential protective effect 
of hormonal contraceptives on non- contact ACL injuries, 
but their conclusions are also variable. The purpose of 
this systematic review and meta- analysis is to, identify, 
evaluate and summarise the effects of endogenous 
and exogenous ovarian hormones on AK laxity (primary 
outcome) and the occurrence of non- contact ACL injuries 
(secondary outcome) in women. We will perform a 
systematic search for all observational studies conducted 
on this topic. Studies will be retrieved by searching 
electronic databases, clinical trial registers, author’s 
personal files and cross- referencing selected studies. 
Risk of bias will be assessed using the Newcastle Ottawa 
Quality Assessment Scale for Cohort and Case–Control 
Studies. Certainty in the cumulative evidence will be 
assessed using the Grading of Recommendations 
Assessment, Development and Evaluation approach. 
The meta- analyses will use a Bayesian approach to 
address specific research questions in a more intuitive 
and probabilistic manner. This review is registered on 
the international database of prospectively registered 
systematic reviews (PROSPERO; CRD42021252365).
BACKGROUND
The participation of girls and women in sport 
has increased worldwide, both in recreational 
and professional practice.1 2 This growth in and 
development of women’s sport has resulted in 
a growing number of reports regarding the 
nature and rate of injuries sustained by sports-
women.3 Depending on the age- group, the 
Key messages
What is already known
 ► Female athletes and exercisers report three to six times 
more anterior cruciate ligament (ACL) injuries than men. 
Most of them happen with a non- contact mechanism.
 ► The differences in reproductive hormone profiles be-
tween men and women have been identified as a risk 
factor for non- contact ACL injuries.
 ► Despite many studies on variations of anterior knee (AK) 
laxity and the rate of non- contact ACL injuries amongst 
normally menstruating participants and hormonal con-
traceptive users, the inconsistency of the literature 
makes it difficult to evaluate the effects of endogenous 
and exogenous ovarian hormones on AK laxity and the 
occurrence of non- contact ACL injuries.
What this study could add
 ► By including both anterior knee (AK) laxity and the oc-
currence of non- contact ACL injuries in naturally men-
struating women, women with menstrual irregularities 
and hormonal contraceptive users, we will provide a 
detailed summary and interpretation of the current state 
of the art of this topic, following a theoretical biological 
pathway from mechanism to outcome.
 ► This study will be the most comprehensive review 
to date of AK laxity and the occurrence of non- 
contact ACL injuries, due to the diversity of included 
participants.
 ► The findings of this review will make the available ev-
idence more accessible to practitioners and will there-
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sport and the level of practice, women report different rates 
of musculoskeletal, sports- related injuries than their male 
counterparts.4 As one of the most prominent musculoskel-
etal injuries, exercising women report three to six times 
more ACL tears than men,5 which occur, in the majority 
of cases, via a non- contact mechanism.6 Most non- contact 
ACL injuries happen during fast- paced multidirectional 
activities (eg, snow skiing, netball, football, rugby, gymnas-
tics).7 The sex disparity for non- contact ACL injuries starts 
at the adolescent growth spurt and peaks during adoles-
cence.8 This sex difference has been attributed to several 
factors that also emerge at this time, namely: anatomical 
(eg, laxity, body composition), physiological (especially 
hormonal), biomechanical, neuromuscular recruitment 
patterns9 and gendered factors present in the develop-
mental environment.10 The potential impact of hormones 
on the mechanisms underpinning non- contact ACL 
injuries deserves greater attention given the numerous 
differences in the concentration of reproductive hormones 
between sexes and the time course of reproductive endo-
crinology, especially in women.
Ovarian hormone profiles vary between and within 
women and are not stable over a women’s lifespan (eg, 
they change across phases of the menstrual cycle, as a 
result of hormonal contraceptive use, during pregnancy 
and following menopause). Ovarian hormones influence 
the structure of all soft tissues (ie, muscles, tendons, and 
ligaments) by determining their collagen metabolism 
(Liu et al11: data from rabbits; Yu et al12 and Konopka et 
al13: data from human ACL cells), and structural integ-
rity (Konopka et al13: data from human ACL cells; Lee 
et al14: data from engineered ligaments). Alterations of 
the ACL structure, caused by fluctuations in ovarian 
hormone levels, may increase the risk for potential liga-
ment failure (Lee et al14: data from engineered ligaments; 
Yu et al12: data from human ACL cells). Indeed, it has 
been suggested that women’s ACLs and musculoskeletal 
systems react to changes in the reproductive hormone 
milieu, thus changing their properties at certain points 
of the lifespan corresponding to different hormonal 
profiles.15
In the last two decades, many studies have shown that 
anterior knee (AK) laxity16 and the rate of non- contact 
ACL injuries17 change during different phases of the 
menstrual cycle in eumenorrheic women, although the 
findings from studies in this area are inconsistent. Several 
studies have also been conducted on the potential protec-
tive effect of hormonal contraceptives, especially oral 
contraceptive pills (OCPs), on non- contact ACL injuries, 
due to their users having a consistently downregulated 
endogenous ovarian hormone profile, although these 
data are also inconsistent.18 These inconsistencies in 
findings (ie, menstrual cycle phase and OCP use) might 
be due to poor methodological quality, especially with 
regards to the definition and confirmation of menstrual 
cycle phases and the heterogeneity of hormonal contra-
ceptives used in these studies (for a comprehensive 
overview of methodological issues see Elliott- Sale et al19).
A systematic review and meta- analysis published in 
201718 concluded that the quality of evidence (ie, data 
published up to August 2016), on the effect of the 
menstrual cycle and hormonal contraceptives on the 
laxity of the ACL and the occurrence of non- contact 
injuries to the ACL, was ‘very low’, due to numerous 
methodological shortcomings affecting the eligibility 
of the participants. Our systematic review and meta- 
analysis will expand the review by Herzberg et al18 by: 
(i) including studies published up to and since August 
2016, (ii) performing a meta- analysis on the injury data 
and not just the laxity data, (iii) employing different 
inclusion/exclusion criteria and (iv) including women 
with menstrual irregularities. In addition, our review 
will adopt a different statistical method (ie, a Bayesian 
approach) to allow for a more intuitive and probabilistic 
synthesis and interpretation of existing data. There-
fore, the purpose of this systematic review is to identify, 
evaluate and summarise the effects of endogenous and 
exogenous ovarian hormones on knee joint laxity and 
occurrence of non- contact injuries of the ACL in women. 
We hypothesise that: (i) AK laxity will differ in response 
to the fluctuations in endogenous ovarian hormones that 
occur at different phases of the menstrual cycle, leading 
to an increased occurrence of non- contact ACL injury, 
(ii) AK laxity and the occurrence of non- contact ACL 
injury would be greater in non- hormonal contraceptive 
users.
METHODS
The protocol for this aetiology systematic review and 
meta- analysis follows the Preferred Reporting Items for 
Systematic Review and Meta- Analysis Protocols20 and the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) for Searching (PRISMA- S)21 
and is registered with the International Prospective 
Register of Systematic Reviews (PROSPERO) registration 
number CRD42021252365.
Eligibility criteria
Studies will be selected according to the PECOS (ie, 
participants, exposures, comparator, outcomes, study 
designs) criteria (table 1). There will be no restrictions 
on the time frame or setting of the studies. Studies 
reported in English, French, Spanish, Portuguese and 
German languages will be considered. A list of possibly 
relevant titles in other languages will be provided as an 
appendix if relevant.
Information sources
Search strategies will be developed using text words 
related to the population, exposures and outcomes. Five 
electronic databases will be searched from their incep-
tion onwards: PubMed Central (includes MEDLINE), 
SPORTDiscus (via EBSCOhost interface), Scopus, the 
Cochrane Central Register of Controlled Trials and 
ProQuest Central: Health and Medical Collection; 
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and Medicine. The electronic database search will be 
supplemented by searching for trial protocols through 
three registers: Clinical Trials ( www. clinicaltrials. gov), EU 
Clinical Trials Register ( www. clin ical tria lsre gister. eu) and 
International Standard Randomised Controlled Trial 
Number (ISRCTN) ( www. isrctn. com). To ensure litera-
ture saturation, the reference lists of included studies or 
relevant reviews identified, which may have been identi-
fied through the initial search strategy, will also be hand 
searched. All authors will search their personal files to 
make sure that all relevant material has been identified.
Search strategy
The PubMed Central search strategy will be developed 
with input from all authors using the Peer Review of 
Electronic Search Strategies standard.22 In addition, 
the search strategy will be peer- reviewed by a research 
librarian who has expertise in systematic review searching 
and is not otherwise associated with the project. A draft 
search strategy for PubMed Central is included in online 
supplemental file 1. Once the PubMed Central search 
strategy is finalised, the search strategy will be adapted to 
the syntax and subject headings of the other databases. 
The search will be updated toward the end of the review, 
prior to publication, to retrieve any articles published 
during the interim period.
Study record
All search results will be uploaded and stored in a system-
atic review management platform (Covidence systematic 
review software, Veritas Health Innovation, Melbourne, 
Australia), which will be accessible to all reviewers. Covi-
dence will automatically remove duplicates by checking 
the following fields: titles, year, volume, authorship. 
Two reviewers will independently check the duplicates 
removed by Covidence and verify their accuracy.
Titles and abstracts will be independently screened 
by two reviewers, guided by the inclusion and exclusion 
criteria. Disagreements will be resolved with a consensus- 
based discussion, and, when in doubt, articles will be 
carried forward to full- text review. The full text of eligible 
papers, based on the titles and abstracts, will be down-
loaded and independently screened. If the reviewers are 
not in agreement, a third reviewer will be consulted and 
will provide recommendations. The reviewers will use the 
annotation facility on the decision dashboard to explain 
their decision and inform further discussions. If a study 
is reported in more than one publication, the multiple 
Table 1 Overview of PECOS eligibility criteria
Participants Human female athletes (defined as one who takes part in an individual or organised team sport wherein: (i) they compete 
regularly against others; (ii) excellence and achievement are emphasised and (iii) systematic intensive training is 
required32) and female exercisers (defined as one who engages in physical activity with the will to: (i) augment their fitness 
level; (ii) improve their health; (iii) ameliorate their physique and (iv) acquire or improve skills33) of reproductive age (ie, 
postmenarche and premenopausal) will be included. Specifically, eumenorrheic, naturally menstruating women, women 
with menstrual irregularities (eg, oligomenorrhoea, polymenorrhoea, amenorrhoea, anovulatory and luteal phase deficient 
cycles) and hormonal contraceptive users (eg, combined and progestogen- only OCPs, injections, implants, patches, 
intra- uterine systems) will be included; with pregnant and perimenopausal women excluded. Participants must not be 
using any form of medication known to affect ovarian hormone profiles (with the exception of hormonal contraceptives) or 
the musculoskeletal system.
Exposures Of interest will be habitual exposures affecting the endogenous ovarian hormone status of the participants; that is, 
menstrual cycle and associated disturbances and hormonal contraceptives.
Comparators Where relevant, hormonal contraceptive users will be compared with non- hormonal contraceptive users.
Outcomes Outcomes relating to the physical assessment of AK laxity (primary outcomes) and the occurrence of non- contact ACL 
injuries (secondary outcomes). The primary outcomes are focused on micro changes (ie, physiological changes to the AK 
laxity that potentially occur due to changes in ovarian hormone concentrations) and the secondary outcomes are focused 
on macro changes (ie, number of non- contact ACL injuries that may potentially occur due to micro changes).
AK laxity refers to the degree of tightness/looseness of the AK in a sagittal plan; in the knee, ligaments are present to 
connect and stabilise the various bones that are present by keeping the knee joint flexible enough to move but also firm 
enough to provide support. It is measured using (i) clinical examination (eg, Lachman test—manual test to assess the AK 
laxity; subjective measure) and (ii) equipment designed to evaluate the AK laxity by quantifying the anterior displacement 
of the anterior tibial tubercle relative to the femur when a predefined anteriorly directed force is applied, from the upper 
calf (eg, arthrometers; objective measure).
Within this systematic review and meta- analysis, we will exclusively focus on studies reporting primary non- contact ACL 
injuries (defined as sudden- onset injuries resulting from a non- contact mechanism showing no evidence of direct or 
indirect physical disruption or perturbation of the player’s movement pattern by an external source.34
Study designs Observational studies will be considered for inclusion if they meet the following inclusion criteria: (i) published, in full, in 
a peer- reviewed journal; (ii) have the objective of assessing changes in AK laxity in response to phases of the menstrual 
cycle, menstrual irregularities and/or hormonal contraceptive use and (iii) report the incidence of ACL injuries aligned 
with phases of the menstrual cycle, menstrual irregularities and/or hormonal contraceptive usage. Cohort studies and 
case–control studies will be included when reporting primary outcomes (ie, the physical assessment of AK laxity). Cross- 
sectional studies, cohort studies and case–control studies will be included when reporting secondary outcomes (ie, the 
occurrence of non- contact ACL injuries). Case studies, review articles, protocol papers, editorials, conference abstracts 
and commentaries will be excluded.
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reports will be collated. When in doubt regarding the 
eligibility criteria of a study, the reviewers will contact the 
authors; with a maximum of three attempts, two emails 
and one phone call (if possible), over a 4- week period. 
Any ongoing trials, which have not yet been reported, will 
be recorded, so that they can be added to the ongoing 
studies table. A PRISMA flowchart detailing the search 
and selection process will be included (see online supple-
mental file 1 for a draft template); as well as a list of all 
full- text studies excluded, detailing the specific reason 
for exclusion.
A data extraction template will be created based 
on those used in similar meta- analyses.23 Data will 
be extracted by two reviewers. To ensure consistency 
across reviewers, calibration exercises will be conducted 
before starting the data collection process (ie, the data 
extraction form will be pilot- tested by each reviewer on 
five randomly selected studies). When outcome data are 
not reported in a usable format (ie, in a figure instead 
of a numerical format) specialist software will be used to 
extract the data from the figure (eg, WebPlotDigitizer 
Version 4.4).
In order to avoid double- counting data, records will be 
scrupulously compared, for example, juxtaposing author 
names, treatment comparisons, sample sizes and/or 
outcomes. If the same study data are reported in more 
than one publication, all publications will be treated 
as one dataset rather than multiple datasets. When we 
extract data, we will prioritise the following criteria: 
greatest number of participants, longest follow- up and 
primary reports where the primary outcome assessed 
is most relevant to our research questions. If the data 
differ across publications, it will be noted, investigated, 
and the authors contacted for more information; with a 
maximum of three attempts, two emails and one phone 
call, over a 4- week period.
Disagreements will be recorded and resolved with a 
consensus- based discussion between the two reviewers. 
Any disagreement that cannot be resolved will be 
referred to a third reviewer who will provide a recom-
mendation. Study authors will be contacted if there are 
any doubts about the extracted data, with a maximum 
of three attempts, two emails and one phone call, over 
a 4- week period. If any disagreement cannot be resolved 
(ie, either through discussion between the reviewers or 
with the authors) the disagreement will be reported in 
the review.
Data items
Reviewers will extract data on the following: (i) study 
characteristics (ie, design, location, sources of funding, 
study aim), (ii) participant characteristics (ie, eligibility 
criteria, age, height, body mass, body mass index, training 
status, etc), (iii) exposure and comparison characteristics 
(ie, type, dosage, and duration of hormonal contraceptive 
use, menstrual cycle phase, type of menstrual irregu-
larity, methods of determining participants’ ovarian 
hormonal status, etc), (iv) outcome characteristics for 
AK (ie, method of assessment, assessment characteris-
tics, etc) and occurrence of ACL injuries (ie, method(s) 
used to confirm the injury, profile of the injury (injury 
mechanism, context of the injury, primary or recurrent 
injury, isolated ACL injury or other collateral structures 
injured), etc).
Outcomes and prioritisation
The primary outcomes are the physical assessment of AK 
laxity and the secondary outcomes are the occurrence of 
non- contact ACL injuries.
Risk of bias assessment
Risk of bias will be initially evaluated at the individual 
study level, using the Newcastle Ottawa Quality Assess-
ment Scale for Cohort or Case–Control Studies.24 The 
Newcastle Ottawa Quality Assessment Scale is a domain- 
based risk of bias tool that comprises eight items within 
three categories to assess the key bias domains: (i) selec-
tion; (ii) comparability and (iii) outcome/exposure. We 
have developed coding systems, that are very similar to 
formerly published work in our research area,25 according 
to our outcomes (ie, anterior knee laxity and ACL injury 
occurrence) and ensured that the assessment is specific 
to each outcome. We have opted for using the Newcastle 
Ottawa Quality Assessment Scale without the star- rating 
system, as the PRISMA explanation and elaboration26 
states that presenting assessments for each domain in 
the tool is preferable to reporting an overall ‘quality 
score’ because it enables users to understand the specific 
domains that are at risk of bias in each study. Accord-
ingly, we will separate the key bias domains covered by 
the Newcastle Ottawa Quality Assessment Scale when 
assessing bias and we will present the results in a table.
Certainty in cumulative evidence
Certainty will be assessed by two independent reviewers 
using a strategy based on the recommendations of the 
Grading of Recommendations Assessment Develop-
ment and Evaluation working group.27 Any differences 
between reviewers will be resolved by discussion and, if 
needed, in consultation with a third reviewer. Certainty 
in cumulative evidence will be based on consideration 
of five domains, namely risk of bias (assessed using the 
NOS as described above), indirectness, inconsistency, 
imprecision or evidence of publication bias. Directness 
will be ascertained based on the methods used to iden-
tify and confirm menstrual cycle phase, along with injury 
confirmation. This information is considered essential, 
given that if unconfirmed, any result observed cannot be 
directly attributed to the phase under investigation. This 
will be evaluated based on the response to two questions:
(Q1) Was the ovarian hormone profile confirmed?
If the authors provide a definition for the sampled 
population and report using blood samples to confirm 
ovarian hormone status, the a priori rating will be main-
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study that is classified as ‘high’ quality, would be down-
graded to ‘moderate’ quality).
(Q2) Was the injury medically diagnosed either as part 
of the study or prior to the study?
These questions are based on methodological conclu-
sions made in previous studies.18 23
Consistency will be ascertained using the meta- 
analysis results and will be based on visual inspection of 
effect size and variance estimates across the different 
levels (eg, within study variation, between study vari-
ation and between outcome variation). Precision will 
be judged based on the number of outcomes available 
(with outcomes based on <3 data points downgraded) 
and on interpretation of width of the credible intervals 
(CrIs). Small- study effects (ie, publication bias) will be 
visually inspected with funnel plots and quantified with 
a multi- level extension of Egger’s regression- intercept 
test.28 Collectively, these procedures will result in a 
final level of certainty for each outcome (table 2): 
namely of ‘high’, ‘moderate’, ‘low’ or ‘very low’. This 
certainty appraisal strategy will not be used to exclude 
any study.
Data synthesis
Data will be presented in summary tables, which will 
describe the study characteristics and outcomes. A 
Bayesian framework was chosen over a frequentist 
approach as it provides a more flexible modelling 
approach that will enable results to be interpreted intui-
tively through reporting of subjective probabilities rather 
than null hypothesis tests or frequentist CIs.29 For the 
primary outcomes comprising assessment of menstrual 
cycle phase, menstrual irregularities and hormonal 
contraceptive use on AK laxity, both repeated measures 
data and independent group data will be used to create 
standardised mean difference effect sizes. Standard 
distributional assumptions will be used to estimate within 
study sampling error.30 For repeated measures data where 
a correlation value is required, a standard value of 0.7 will 
be used to generate an informative prior with variance 
included to account for correlations ranging from 0.5 to 
0.9. For the secondary outcome comprising the occur-
rence of ACL injuries, count data will be used to calculate 
ORs and within study sampling error. All meta- analyses will 
comprise a three- level hierarchical model to account for 
random variation across studies and covariance between 
multiple outcomes reported from the same study. Infer-
ences from all analyses will be performed on posterior 
samples generated by Hamiltonian Markov Chain Monte 
Carlo with Bayesian 95% CrIs. Interpretations will be 
based on visual inspection of the posterior sample, the 
median pooled effect size value (ES
0.5
: 0.5- quantile) and 
95% CrIs for location parameters and 75% CrIs for vari-
ance parameters. Heterogeneity will be quantified using 
the posterior distribution of the between study variance 
parameter. Where possible, meta- regressions will be 
used to explore sources of variance including the type 
of hormonal contraceptive (eg, OCPs, implants, injec-
tions, etc). Meta- regression will be performed when 
there is sufficient data including a minimum of four data 
points per category level or 10 data points for continuous 
variables.31 Sensitivity analyses will also be conducted 
to assess the influence of research quality (inclusion of 
‘moderate’ and ‘high’ quality studies only) on overall 
conclusions and effect size magnitudes. Results of meta- 
analyses will be presented in tables and visually through 
forest and funnel plots. Where quantitative pooling is not 
possible due to insufficient data, narrative synthesis will 
be conducted.
DISCUSSION
This systematic review and meta- analysis will synthetise 
evidence to evaluate the effects of various levels of endog-
enous and exogenous ovarian hormones on AK laxity and 
the occurrence of non- contact ACL injuries in women. 
By including both AK laxity and the occurrence of non- 
contact ACL injuries in naturally menstruating women, 
women with menstrual irregularities and hormonal 
contraceptive users, we will provide an up- to- date, 
detailed summary and interpretation of the current state 
of the art of this topic. Furthermore, this meta- analysis 
will examine the strength of the outcomes and indicate 
methodological considerations for future research. The 
findings of this review will have practical implications 
for female athletes (elite to recreational) and for those 
working with active women.
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Table 2 Significance of the four certainty of evidence categories35
High Confident that the true effect lies close to that of the estimate of the effect
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possibility that it is substantially different
Low Confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
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